Navigation Links
Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
Date:10/31/2011

MELBOURNE, Australia, Oct. 31, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate clinical trials of VGX-100. The first trial (Phase I) will study VGX-100 in patients with a variety of late stage cancers.

"The FDA's acceptance of our IND represents an extremely important milestone for Circadian. We are well advanced in finalizing clinical trial sites in the USA and expect clinical trials to commence before the end of 2011 with results becoming available from the study in the second half of 2012," said Robert Klupacs, CEO of Circadian Technologies Limited.

VGX-100 is a human antibody that acts against the human VEGF-C protein. Treatment for cancers, particularly glioblastoma and metastatic colorectal cancers, are the first target indications for VGX-100. Additionally, Circadian is developing VGX-100 for a number of other cancer indications, as well as an agent to treat front-of the-eye diseases.

Studies in animal model studies across a wide range of tumour types have shown that when combined with Avastin® and chemotherapy, VGX-100 can significantly reduce tumour growth and tumour spread as well as significantly improve tumour inhibition, over and above that of Avastin® and/or chemotherapy alone. Recent studies have also implicated VEGF-C as a key mediator of disease progression during Avastin® treatment, implying that combination therapy with VGX-100 and Avastin® could significantly improve treatment outcomes in cancer patients.

Circadian's wholly owned subsidiary, Vegenics Pty Ltd, owns worldwide rights to an extensive intellectual property portfolio covering the angiogenesis and lymphangiogenesis targets VEGF-C, VEGF-D and the receptor protein VEGFR-3. Vegenics has also been granted exclu
'/>"/>

SOURCE Circadian Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems
4. Mylan Receives Approval for Generic Version of MS Contin® Tablets
5. SAFC Verona HPAPI Manufacturing Facility Receives SafeBridge Certification
6. INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
7. Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System
8. Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
9. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
10. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
11. Institute of Health Sciences Receives ABHES Institutional Accreditation for Long Distance Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- "North America Orthopedic Braces and Supports Market Outlook ... America Orthopedic Braces and Supports market. The report provides ... units) and average price data (in US dollars), within ... , Ankle Braces and Supports , Spinal ... Supports. Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
(Date:7/24/2014)... Inc. (NASDAQ: QCOR ) today reported financial results ... Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ChangeGAAP Net Sales ... Net Sales , $278.8 Million , $196.1 Million , ... $1.12 , 37% Non-GAAP Diluted EPS , ... Months Ended 06/30/14Six Months Ended 06/30/13 ,  Percentage ChangeNet Sales ...
(Date:7/24/2014)... July 24, 2014  To help health care ... that could impact patient care and the bottom ... Watch , "Innovations in Cardiovascular Devices."  ... guidance and details on promising new technologies that ... understand how these options impact the supply chain.   ...
Breaking Medicine Technology:North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3
... 8, 2012 In the Middle East and ... in the MENA region are among the top 10 globally ... Arab Emirates, Bahrain, Egypt, Kuwait, Oman and Saudi Arabia. The ... percent of its total health care expenditure and expenditure averages ...
... Corporation (OTCBB: POSC), through its wholly owned subsidiary, ... announce the execution of a Memorandum of Understanding ... Troitsk, Russia. MIT and INR will collaborate on ... exercise in 2012.  A key goal of the ...
Cached Medicine Technology:Meeting of the Region's Top Diabetes Experts in Dubai this March 2Positron Completes Agreement With Institute of Nuclear Research, Troitsk, Russia for Additional Strontium-82 Supply 2Positron Completes Agreement With Institute of Nuclear Research, Troitsk, Russia for Additional Strontium-82 Supply 3
(Date:7/24/2014)... Rochelle, NY, July 24, 2014Malcolm K. Brenner, MD, PhD, ... career in basic and clinical research toward understanding how ... immune defense system, and developing genetically modified T cells ... scientific achievements and leadership in the field, Dr. Brenner ... Human Gene Therapy , a peer-reviewed journal from Mary ...
(Date:7/24/2014)... 24, 2014 The National Resident ... launch of a new version of its smartphone app, ... PRISM, for applicants participating in NRMP’s Main Residency Match® ... track and organize program information during the interview process ... creating their rank order lists. Rank order lists ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical practitioner, ... the youth to persevere in their endeavors to achieve ... youth to stay away from social vices and also ... afford you the opportunity of acquiring life surviving skills ... your career path.” Professionals in the fields of Business, ...
(Date:7/24/2014)... 24, 2014 The European Omega 3 & ... & structured lipids market in Europe with analysis and forecast ... $670.37 million in 2012 to $989.91 million by 2018, at ... through the TOC of the European omega 3 & structured ... analysis provided. This also provides a glimpse of the segmentation ...
(Date:7/24/2014)... Boston Children’s Museum opens a new exhibit ... and created through a partnership between Boston Children’s Museum ... immersive and inspiring traveling exhibit designed to engage adults ... of astronomical science. It is accompanied by a ... the universe, reveals secrets of the sky, and offers ...
Breaking Medicine News(10 mins):Health News:Malcolm K. Brenner receives Pioneer Award for advances in gene-modified T cells targeting cancer 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 3Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:My Sky Exhibit Opens at Boston Children’s Museum 2Health News:My Sky Exhibit Opens at Boston Children’s Museum 3Health News:My Sky Exhibit Opens at Boston Children’s Museum 4Health News:My Sky Exhibit Opens at Boston Children’s Museum 5
... Supported Efficacy, Safety and Tolerability of ... with Schizophrenia -, TOKYO and PRINCETON, N.J., ... Squibb Company (NYSE: BMY ) announced today ... the supplemental New,Drug Application for the atypical antipsychotic ...
... be lifesavers, study suggsts , TUESDAY, Nov. 6 (HealthDay ... artery bypass graft (CABG) surgery reduces a patient,s risk ... the Cleveland Clinic, included more than 5,200 patients who ... overall incidence of post-operative stroke one year after surgery ...
... To help raise awareness about the,prevalence of ... serving our country, TriWest Healthcare Alliance has contributed,$50,000 ... TBI. "According to the Department of Defense, ... members sustaining injuries in the Global War,on Terror ...
... Focus on Growth Businesses, LEHIGH VALLEY, Pa., Nov. ... Chemie AG are in advanced discussions over Wacker,s,purchase of ... Systems (WPS) and Air Products Polymers (APP), including APP,s,vinyl ... and,Wacker 35 percent. As for WPS, Wacker owns 80 ...
... 7 The Disabled American,Veterans (DAV) is commending ... the largest increase in funding for the Department ... on Congress and the,Administration to support this important ... Military Construction and Veterans Affairs Appropriations bill,calls for ...
... QED International Associates Inc.,administrator for the HealthShares(TM) ... today announced that effective at the,opening of trading ... GIVN ) will replace Dade Behring Holdings, ... Index, and Inverness Medical Innovations,(Amex: IMA ) ...
Cached Medicine News:Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 2Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 3Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 4Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 5Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 6Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 7Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 8Health News:TriWest Contributes $50,000 to Bob Woodruff Family Fund for Traumatic Brain Injury 2Health News:Air Products in Advanced Discussions With Wacker Over Polymers Business 2Health News:VA Budget Earns High Praise 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Composite, and the HealthShares(TM) Diagnostics Indexes 2
This kit has been designed for the quantitative,determination of total immunoreactive intact PTH (Total,Intact PTH) in blood samples. The Total Intact PTH,level is the sum of PTH (1-84) and N-t...
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma....
... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
Medicine Products: